Introduction to Survodutide Research Survodutide represents a novel class of therapeutic peptides currently dominating 2026 metabolic and hepatic research. Co-invented by Boehringer Ingelheim and Zealand Pharma, survodutide is a dual agonist that targets both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). This dual mechanism differentiates it from selective GLP-1 agonists and has […]
